相关实验视频

Updated: Jul 5, 2025

Intracranial Pharmacotherapy and Pain Assays in Rodents

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

一种新型的leu-enkephalin产药产生了缓解疼痛和抗抑郁作用

Lukas Hohenwarter¹, Ernest Puil², Elham Rouhollahi¹

¹Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada.

Molecular pharmaceutics

|January 20, 2024

概括

一种新的白-脑原药,KK-103,显示出治疗慢性疼痛和抑郁症的前景. 它有效地减轻疼痛,并表现出类似抗抑郁药的活性,副作用比目前的治疗方法少.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
疼痛管理疼痛管理

背景情况:

持续性疼痛和抑郁症是医疗保健面临的重大挑战,有效治疗方法有限.
目前的抗抑郁药和阿片类药物存在局限性,包括副作用和对并发症的有效性降低.
氨酸-脑素 (Leu-ENK),一种内源性阿片类药物,可以控制疼痛和情绪,但稳定性不佳.

研究的目的:

评估KK-103,一种新的Leu-ENK前药物,用于增强疼痛和抑郁症的稳定性和治疗潜力.
评估KK-103的药理动力学特征和中枢神经系统的吸收.
为了确定KK-103的抗受体和抗抑郁药类疗效.

主要方法:

开发KK-103,一种 Leu-ENK 前药,具有增加的血稳定性.
用小鼠进行的药理动力学研究,以评估放射性标记的KK-103的系统吸附和大脑吸收.
在体内使用升级式热板和甲胺试验进行抗受体试验.
评估抗抑郁药类活性和副作用 (胃肠道抑制,镇静).

主要成果:

与Leu-ENK相比,KK-103的血稳定性和全身暴露显著增加.
被放射性标记的KK-103在大脑中被吸收,这表明透了中枢神经系统.
在已建立的疼痛模型中,KK-103表现出长期的抗痛感疗效.
KK-103产生的抗抑郁药类似的效果相当于desipramine,与最小的胃肠道抑制和没有镇静.

结论:

KK-103是一种有前途的 Leu-ENK 前药,可以克服本土 Leu-ENK 的局限性.
KK-103通过三角类阿片类受体激活有效地准疼痛和情绪调节.
这种新型化合物为并发性慢性疼痛和抑郁症提供了潜在的治疗策略,并改善了安全性.

关键词:

这是一种反感 (antinociception).行为研究行为研究.抑郁抑郁症抑郁症抑郁症抑郁症脑袋和脑袋中的一个.这是一种神经,神经.疼痛疼痛疼痛疼痛药物动力学药物动力学

更多相关视频

Author Spotlight: Enhanced Method for Evaluating Analgesic Effects — Dual Hind Paw Carrageenan Injection in Mice

Author Spotlight: Enhanced Method for Evaluating Analgesic Effects — Dual Hind Paw Carrageenan Injection in Mice

Published on: November 15, 2024

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

相关概念视频

Analgesia and Pain Management

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...